Literature DB >> 21412167

Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer.

Mustafa Abdel Hafiz El Sherbini1, Maha Mohamed Sallam, Emtiaz Abdel Kawy Shaban, Amr Hassan El-Shalakany.   

Abstract

OBJECTIVES: To assess the diagnostic value of serum KLK6 and KLK10 in patients with ovarian tumor in comparison to serum CA125.
METHODS: Based on clinical and sonographic findings, 90 patients were consecutively recruited at the Gynecological Oncology Unit, Ain Shams University Maternity Hospital. Preoperative serum KLK6 and/or KLK10 were determined by enzyme-linked immunosorbent assay technique. The patients' final diagnoses were those of the histopathological reports.
RESULTS: There were 27 malignant versus 63 benign cases. Serum markers' diagnostic specificity and sensitivity were 80.3/72.7, 56.8/64.0, and 39.53/58.3 for CA125, KLK6, and KLK10, respectively. Combination of CA125 with either of the other 2 markers revealed diagnostic enhancement with KLK10 (85.37/73.00) but not with KLK6 (42.86/86.36).
CONCLUSIONS: In ovarian cancer, serum KLK6 and KLK10 may have much lower overall sensitivities than serum CA125. However, whereas serum KLK6 may improve the sensitivity of CA125, serum KLK10 may have the highest specificity among the 3 markers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412167     DOI: 10.1097/IGC.0b013e31821283c3

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

Review 1.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

2.  Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.

Authors:  Ayala Tamir; Ushma Jag; Sreeja Sarojini; Craig Schindewolf; Takemi Tanaka; Rajendra Gharbaran; Hiren Patel; Anil Sood; Wei Hu; Ruzeen Patwa; Patrick Blake; Polina Chirina; Jin Oh Jeong; Heejin Lim; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Ovarian Res       Date:  2014-12-05       Impact factor: 4.234

3.  Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.

Authors:  Xiaocong Geng; Yueyang Liu; Sandra Diersch; Matthias Kotzsch; Sabine Grill; Wilko Weichert; Marion Kiechle; Viktor Magdolen; Julia Dorn
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

Review 4.  Prediction of the treatment response in ovarian cancer: a ctDNA approach.

Authors:  Mina Sharbatoghli; Somayeh Vafaei; Hamidreza Aboulkheyr Es; Mohsen Asadi-Lari; Mehdi Totonchi; Zahra Madjd
Journal:  J Ovarian Res       Date:  2020-10-19       Impact factor: 4.234

5.  Identification of human tissue kallikrein 6 as a potential marker of laryngeal cancer based on the relevant secretory/releasing protein database.

Authors:  Ying Zhang; Zaixing Zhang; Lei Yang; Bin Xu; Weihua Li; Pingzhang Tang; Zongmin Zhang; Naijun Han; Yanning Gao; Shujun Cheng; Ting Xiao
Journal:  Dis Markers       Date:  2014-02-11       Impact factor: 3.434

6.  Diagnostic value of KLK6 as an ovarian cancer biomarker: A meta-analysis.

Authors:  Fan Yang; Zhi-DE Hu; Yingjian Chen; Cheng-Jin Hu
Journal:  Biomed Rep       Date:  2016-04-21

7.  KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study.

Authors:  Mustafa A El Sherbini; Amal A Mansour; Maha M Sallam; Emtiaz A Shaban; Zeinab A Shehab ElDin; Amr H El-Shalakany
Journal:  J Ovarian Res       Date:  2018-04-24       Impact factor: 4.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.